vs

Side-by-side financial comparison of BENCHMARK ELECTRONICS INC (BHE) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

BENCHMARK ELECTRONICS INC is the larger business by last-quarter revenue ($677.3M vs $622.0M, roughly 1.1× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 1.9%, a 32.5% gap on every dollar of revenue. On growth, BENCHMARK ELECTRONICS INC posted the faster year-over-year revenue change (11.4% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -0.7%).

Benchmark Electronics Inc is an EMS, ODM, and OEM company based in Tempe, Arizona in the Phoenix metropolitan area. It provides contract manufacturing services.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

BHE vs RPRX — Head-to-Head

Bigger by revenue
BHE
BHE
1.1× larger
BHE
$677.3M
$622.0M
RPRX
Growing faster (revenue YoY)
BHE
BHE
+6.6% gap
BHE
11.4%
4.8%
RPRX
Higher net margin
RPRX
RPRX
32.5% more per $
RPRX
34.4%
1.9%
BHE
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-0.7%
BHE

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BHE
BHE
RPRX
RPRX
Revenue
$677.3M
$622.0M
Net Profit
$13.0M
$214.2M
Gross Margin
10.2%
Operating Margin
3.2%
62.4%
Net Margin
1.9%
34.4%
Revenue YoY
11.4%
4.8%
Net Profit YoY
257.4%
2.9%
EPS (diluted)
$0.17
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BHE
BHE
RPRX
RPRX
Q1 26
$677.3M
Q4 25
$725.8M
$622.0M
Q3 25
$702.6M
$609.3M
Q2 25
$665.7M
$578.7M
Q1 25
$654.6M
$568.2M
Q4 24
$683.6M
$593.6M
Q3 24
$680.0M
$564.7M
Q2 24
$686.7M
$537.3M
Net Profit
BHE
BHE
RPRX
RPRX
Q1 26
$13.0M
Q4 25
$214.2M
Q3 25
$14.3M
$288.2M
Q2 25
$972.0K
$30.2M
Q1 25
$3.6M
$238.3M
Q4 24
$208.2M
Q3 24
$15.4M
$544.0M
Q2 24
$15.5M
$102.0M
Gross Margin
BHE
BHE
RPRX
RPRX
Q1 26
10.2%
Q4 25
10.2%
Q3 25
9.7%
Q2 25
9.7%
Q1 25
9.7%
Q4 24
9.9%
Q3 24
9.8%
Q2 24
9.9%
Operating Margin
BHE
BHE
RPRX
RPRX
Q1 26
3.2%
Q4 25
2.8%
62.4%
Q3 25
3.4%
70.1%
Q2 25
3.1%
36.3%
Q1 25
1.8%
94.0%
Q4 24
4.2%
60.9%
Q3 24
4.1%
Q2 24
4.0%
50.2%
Net Margin
BHE
BHE
RPRX
RPRX
Q1 26
1.9%
Q4 25
34.4%
Q3 25
2.0%
47.3%
Q2 25
0.1%
5.2%
Q1 25
0.6%
41.9%
Q4 24
35.1%
Q3 24
2.3%
96.3%
Q2 24
2.3%
19.0%
EPS (diluted)
BHE
BHE
RPRX
RPRX
Q1 26
$0.17
Q4 25
$0.16
$0.49
Q3 25
$0.39
$0.67
Q2 25
$0.03
$0.07
Q1 25
$0.10
$0.55
Q4 24
$0.43
$0.46
Q3 24
$0.42
$1.21
Q2 24
$0.43
$0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BHE
BHE
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$324.9M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$9.7B
Total Assets
$2.1B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BHE
BHE
RPRX
RPRX
Q1 26
$324.9M
Q4 25
$322.1M
$618.7M
Q3 25
$285.4M
$938.9M
Q2 25
$264.6M
$631.9M
Q1 25
$355.3M
$1.1B
Q4 24
$315.2M
$929.0M
Q3 24
$324.4M
$950.1M
Q2 24
$309.3M
$1.8B
Total Debt
BHE
BHE
RPRX
RPRX
Q1 26
Q4 25
$206.8M
$9.0B
Q3 25
$212.6M
$8.9B
Q2 25
$203.4M
$8.0B
Q1 25
$268.9M
$7.6B
Q4 24
$250.5M
$7.6B
Q3 24
$272.0M
$7.6B
Q2 24
$283.6M
$7.6B
Stockholders' Equity
BHE
BHE
RPRX
RPRX
Q1 26
Q4 25
$1.1B
$9.7B
Q3 25
$1.1B
$9.6B
Q2 25
$1.1B
$9.5B
Q1 25
$1.1B
$9.8B
Q4 24
$1.1B
$10.3B
Q3 24
$1.1B
$10.3B
Q2 24
$1.1B
$9.8B
Total Assets
BHE
BHE
RPRX
RPRX
Q1 26
$2.1B
Q4 25
$2.1B
$19.6B
Q3 25
$2.1B
$19.3B
Q2 25
$2.0B
$18.3B
Q1 25
$2.1B
$17.6B
Q4 24
$2.1B
$18.2B
Q3 24
$2.1B
$18.0B
Q2 24
$2.2B
$17.7B
Debt / Equity
BHE
BHE
RPRX
RPRX
Q1 26
Q4 25
0.19×
0.92×
Q3 25
0.19×
0.93×
Q2 25
0.18×
0.84×
Q1 25
0.24×
0.78×
Q4 24
0.23×
0.74×
Q3 24
0.25×
0.74×
Q2 24
0.26×
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BHE
BHE
RPRX
RPRX
Operating Cash FlowLast quarter
$47.0M
$827.1M
Free Cash FlowOCF − Capex
$48.1M
FCF MarginFCF / Revenue
7.1%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.61×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$108.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BHE
BHE
RPRX
RPRX
Q1 26
$47.0M
Q4 25
$58.7M
$827.1M
Q3 25
$36.6M
$702.6M
Q2 25
$-2.8M
$364.0M
Q1 25
$31.5M
$596.1M
Q4 24
$45.9M
$742.5M
Q3 24
$39.0M
$703.6M
Q2 24
$55.8M
$658.2M
Free Cash Flow
BHE
BHE
RPRX
RPRX
Q1 26
$48.1M
Q4 25
$48.2M
Q3 25
$25.8M
Q2 25
$-13.8M
Q1 25
$28.1M
Q4 24
$37.2M
Q3 24
$29.2M
Q2 24
$48.2M
FCF Margin
BHE
BHE
RPRX
RPRX
Q1 26
7.1%
Q4 25
6.6%
Q3 25
3.7%
Q2 25
-2.1%
Q1 25
4.3%
Q4 24
5.4%
Q3 24
4.3%
Q2 24
7.0%
Capex Intensity
BHE
BHE
RPRX
RPRX
Q1 26
Q4 25
1.4%
Q3 25
1.5%
Q2 25
1.7%
Q1 25
0.5%
Q4 24
1.3%
Q3 24
1.4%
Q2 24
1.1%
Cash Conversion
BHE
BHE
RPRX
RPRX
Q1 26
3.61×
Q4 25
3.86×
Q3 25
2.57×
2.44×
Q2 25
-2.90×
12.06×
Q1 25
8.65×
2.50×
Q4 24
3.57×
Q3 24
2.54×
1.29×
Q2 24
3.59×
6.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BHE
BHE

Segment breakdown not available.

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons